Homepage Top Section2

The deal is anticipated to close in the second quarter of 2026, subject to standard conditions. The acquisition aims to expand Otsuka’s portfolio in the psychiatric and neurological

The acquisition will provide access to Exl-111, a half-life extended, high-affinity anti-IgE antibody currently in Phase I clinical trials. Designed as an advanced extension of the established biology

The initiative will combine Cognito Therapeutics’ investigational Spectris technology platform with the clinical infrastructure of Ochsner Health to explore innovative approaches to brain health across urban and rural

Cardiac amyloidosis is a progressive condition where misfolded proteins accumulate in the heart muscle, often leading to heart failure. There are two main types of cardiac amyloidosis: wild-type

This collaboration is also aimed at expediting early-phase clinical trials and delivering new therapies to patients. It will leverage both organisations’ expertise to advance healthcare innovation. Each partner

This approval covers adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) who have carcinoma in situ (CIS), with or without papillary tumours. The authorisation follows a review

Under the contract, Novartis will pay $2bn upfront and up to $1bn in milestones to acquire Synnovation Therapeutics’ wholly owned subsidiary Pikavation Therapeutics, which holds SNV4818 and related

The company also secured an exclusive global licence for the development and commercialisation of AP306 with Alebund Pharmaceuticals, excluding Greater China. The funding will support the global development

The regulatory action date for the humanised immunoglobulin G1, kappa (IgG1/k) monoclonal antibody sBLA review is anticipated by 29 October 2026. If approved, this would expand the therapy’s